Khiron has announced that the company has appointed Chris Naprawa as the company’s new Chairman and Board of Director Member. The company’s new Chairman and Board of Director Member would be responsible to guide the company in order to increase its commercialization phase in the market of Latin America. The company has further added that the company’s previous Member of the Audit and Compensation Committees, Michael Berk has resigned from the Board with immediate effect.
Co-Founder and Chief Executive Officer of Khiron, Alvaro Torres said, “I congratulate Chris on this appointment which comes at a dynamic time for the Company. Today we are a recognized cannabis leader in Latin America, generating revenue and market share as the first and only company authorized for low- and high-THC sales in Colombia, and with expanded sales activity in Latin America, Europe and beyond.”
“In his role as President, Chris has played an integral part in these developments and in increasing investor understanding of our business,” Co-Founder and Chief Executive Officer of Khiron added in his statement.
As Chairman, Chris will provide tremendous support and guidance to ensure our focus on a continued and sustainable global growth,” Alvaris Torres further added.
“On behalf of the Board I would also like to thank Michael for his many contributions to Khiron after joining the Company’s Board a year ago. Since then, the Company has achieved many consequential milestones regarding its international growth and has established itself as a leader in the medical cannabis industry within Latin America,” Alvaris Torres continued.
“On a personal note, I am very grateful to Mike for his support and care of the health and safety of our employees during the COVID-19 pandemic. We wish him the best in his future endeavors,” continued Alvaro Torres,” Alvaris Torres concluded.